my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
19-03-2009: Mediwatch plc has signed a five-year agreement for the worldwide distribution of PSAwatch, its flagship point-of-care total PSA measuring system for prostate cancer, with Inverness Medical Innovations, Inc. According to the company, Inverness has an extensive global sales-force which will complement Mediwatch’s own worldwide distribution network and provide the Company with considerably more market reach.
Philip Stimpson, Mediwatch Chief Executive commented: “We are confident that this strategically important distribution agreement will deliver a significant revenue stream. The market for point of care diagnostics is growing rapidly as a result of a combination of; the population aging, growth of local clinics, home testing and the need for faster, cheaper, more portable and easier to use medical equipment. "
Watchlist
This is where you can add this news to your personal favourites
Ascenion Mediates License Agreement for Novel Antibiotic against Tuberculosis
Ascenion announced, that it has negotiated a licensing contract providing Inverness Medical Innovations, Inc. with worldwide, exclusive rights to a novel antibiotic for the treatment of tuberculosis. Ascenion has initiated and mediated the agreement on behalf of an international consortium ... more
Mediwatch secures five year global distribution agreement with Inverness Medical Innovations
Mediwatch plc has signed a five-year agreement for the worldwide distribution of PSAwatch, its flagship point-of-care total PSA measuring system for prostate cancer, with Inverness Medical Innovations, Inc. According to the company, Inverness has an extensive global sales-force which will c ... more
BioCurex Licenses RECAF Technology to Inverness Medical Innovations
BioCurex and Inverness Medical Innovations have announced a licensing agreement for BioCurex's RECAF material and technology. RECAF (the receptor for alpha-fetoprotein) is a wide-spectrum marker present in malignant cancer cells and absent in most normal cells, allowing it to play a major r ... more
Mediwatch secures five year global distribution agreement with Inverness Medical Innovations
Mediwatch plc has signed a five-year agreement for the worldwide distribution of PSAwatch, its flagship point-of-care total PSA measuring system for prostate cancer, with Inverness Medical Innovations, Inc. According to the company, Inverness has an extensive global sales-force which will c ... more
is continually striving to develop and market faster, simpler and less invasive diagnostic products to save lives and restore quality of life for people with a variety of urological conditions. Founded in 1995, Mediwatch has developed a range of point-of-care medical equipment for the diagn ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
